On November 13, the construction of the MSD Animal Health China R&D and Process Technology Center was completed in the Qianwan New Area, Ningbo. The center will become the world's second largest animal vaccine R&D center of the MSD Animal Health. In the future, relying on the localized research and innovation capabilities of China's R&D and Process Technology Center, MSD will provide more high-quality, high-tech, and high value-added animal health products for the Chinese market.
As a leading global biopharmaceutical company, the MSD Animal Health has an industry-leading research and development pipeline for vaccines, chemicals, and technology solutions, as well as a global research and development network and production bases. In 2019, the MSD Animal Health established China's first R&D and production base in the Qianwan New Area. In 2021, it invested over 30 million US Dollars to build the China R&D and Process Technology Center in the Qianwan New Area, which was officially delivered for use in September 2023.
With the completion of the China R&D and Process Technology Center, the MSD Animal Health has successfully completed the business layout of research and development, production, and business in China, entering a new field of animal technology solutions. Through the organic combination of biopharmaceutical and technology solutions, MSD will provide more efficient and comprehensive services to domestic breeding enterprises and pet owners. The head of MSD (Ningbo) Animal Health Technology Co., Ltd. said that the China R&D and Process Technology Center will adhere to global unified R&D standards and processes, continuously introduce innovative technologies, and combine local R&D and production to develop innovative vaccines required by the Chinese market.
As one of the key leading industries planned and developed, in recent years, the life and health industry in the Qianwan New Area has begun to take shape, gradually introducing a series of projects such as the Pharmaron Life Science and Technology Industrial Park with a total investment of 12.6 billion yuan, the Ningbo Kanghui Biopharmaceutical's incubator project with a total investment of 800 million yuan, the MSD's veterinary vaccine production project with a total investment of 310 million US Dollars, the Linfeng Medical Technology Industrial Park project with a total investment of over 600 million yuan, and the Shuangcheng Pharmaceuticals' R&D and production project with a total investment of 1.5 billion yuan and so on, all of which have a total investment of over 18 billion yuan, showing a trend of cluster development.
As of now, the Qianwan New Area boasts more than 70 life and health related enterprises, covering sub fields such as biopharmaceuticals, medical devices and biomedical engineering, modern Chinese medicine, and pharmaceutical research and development service outsourcing, etc., gradually forming a high-end biopharmaceutical industry base that integrates drug research and development, pilot testing, and industrialization. At the same time, the Qianwan New Area has formulated and introduced a new round of industrial and technological policies, actively focusing on the life and health industry. Every year, 50 million yuan is allocated for the special cultivation of the life and health industry, with a focus on providing subsidies for the introduction of high-end life and health industry projects, innovative platform construction, drug and device research and development, and so on.
